- Home
- AIRS vs KPTI Comparison
AIRS vs KPTI Comparison
Compare AIRS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIRS | KPTI |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 197.3M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AIRS | KPTI |
|---|---|---|
| Price | $3.32 | $8.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 1.3M | 481.8K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $151,818,000.00 | $146,067,000.00 |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $5.32 | $22.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $1.51 | $3.65 |
| 52 Week High | $12.00 | $10.99 |
Technical Indicators
Market Signals| Indicator | AIRS | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 65.81 | 58.23 |
| Support Level | $2.43 | $5.84 |
| Resistance Level | $3.36 | $9.00 |
| Average True Range (ATR) | 0.27 | 0.57 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 75.53 | 43.73 |
Price Performance
Historical ComparisonAbout AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).